Natural cannabinoids suppress the cytokine storm in sepsis-like in vitro model (notice n° 236204)

détails MARC
000 -LEADER
fixed length control field 02346cam a2200277 4500500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250112064027.0
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title fre
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Szekely, Yishay
Relator term author
245 00 - TITLE STATEMENT
Title Natural cannabinoids suppress the cytokine storm in sepsis-like in vitro model
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2020.<br/>
500 ## - GENERAL NOTE
General note 45
520 ## - SUMMARY, ETC.
Summary, etc. Natural cannabinoids may have beneficial effects on various tissues and functions including a positive influence on the immune system and the inflammatory process. The purpose of this study was to investigate the effects of natural cannabinoids on the production of pro-inflammatory cytokines by lipopolysaccharide (LPS)-stimulated whole human blood cells. Levels of the pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured before and after exposure of LPS-stimulated whole blood to different concentrations of Cannabidiol (CBD) or a combination of CBD and Tetrahydrocannabinol (THC) extract. LPS stimulated the production of the pro-inflammatory cytokines. Exposure to both CBD and CBD/THC extracts significantly suppressed cytokine production in a dose-dependent manner. Exposure to cannabinoid concentrations of 50 μg/ml or 100 μg/ml resulted in a near-complete inhibition of cytokine production. This study demonstrates that natural cannabinoids significantly suppress pro-inflammatory cytokine production in LPS-stimulated whole blood in a dose-dependent manner. The use of human whole blood, rather than isolated specific cells or tissues, may closely mimic an in vivo sepsis environment. These findings highlight the role that natural cannabinoids may play in suppressing inflammation and call for additional studies of their use as possible novel therapeutic agents for acute and chronic inflammation.
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element cannabinoids
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element sepsis
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element pro-inflammatory cytokines
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element cannabidiol
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element inflammation
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element tetrahydrocannabinol
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Ingbir, Merav
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Bentur, Ohad S.
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Hochner, Ohad
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Porat, Reuven
Relator term author
786 0# - DATA SOURCE ENTRY
Note European Cytokine Network | Volume 31 | 2 | 2020-06-01 | p. 50-58 | 1148-5493
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://shs.cairn.info/revue-european-cytokine-network-2020-2-page-50?lang=en">https://shs.cairn.info/revue-european-cytokine-network-2020-2-page-50?lang=en</a>

Pas d'exemplaire disponible.

PLUDOC

PLUDOC est la plateforme unique et centralisée de gestion des bibliothèques physiques et numériques de Guinée administré par le CEDUST. Elle est la plus grande base de données de ressources documentaires pour les Étudiants, Enseignants chercheurs et Chercheurs de Guinée.

Adresse

627 919 101/664 919 101

25 boulevard du commerce
Kaloum, Conakry, Guinée

Réseaux sociaux

Powered by Netsen Group @ 2025